Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.43 |
| ▸ | NNMT | P40261 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.38 |
| ▸ | OXTR | P30559 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL212945 | 0.99 | MKNK1 (0.46) | MKNK1MKNK2JAK2CYP2A6HSD17B1 | |
| SCHEMBL14007487 | 0.82 | DPP4 (0.49) | MKNK1MKNK2JAK2CYP2A6HSD17B1 | |
| SCHEMBL4619479 | 0.82 | LMNA (0.50) | MKNK1MKNK2JAK2CYP2A6HSD17B1 | |
| SCHEMBL2735125 | 0.81 | LMNA (0.49) | MKNK1MKNK2JAK2CYP2A6HSD17B1 | |
| SCHEMBL18014697 | 0.78 | CYP2A6 (0.47) | MKNK1MKNK2JAK2CYP2A6HSD17B1 | |
| SCHEMBL16629580 | 0.78 | CYP2A6 (0.47) | MKNK1MKNK2JAK2CYP2A6HSD17B1 | |
| SCHEMBL15866832 | 0.73 | DPP4 (0.55) | LMNAPKMKMT2A | |
| SCHEMBL22660623 | 0.72 | HSD17B1 (0.55) | MKNK1MKNK2JAK2CYP2A6HSD17B1 | |
| SCHEMBL13575392 | 0.72 | L3MBTL1 (0.60) | MKNK1MKNK2JAK2CYP2A6HSD17B1 | |
| SCHEMBL10094614 | 0.72 | CYP2A6 (0.61) | MKNK1MKNK2JAK2CYP2A6HSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431573-B2 | Cyanopyrimidinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-30 | — | — | US | disclosed |
| US-8431573-B2 | Cyanopyrimidinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-30 | — | — | US | disclosed |
| US-8088769-B2 | e.g. 2-(3,4-Dichlorophenyl)ethanamidine hydrochloride; phosphodiesterases inhibitor; learning enhancement, cognition activator; improving perception, concentration, or memory | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-03 | — | — | US | disclosed |
| US-8088769-B2 | e.g. 2-(3,4-Dichlorophenyl)ethanamidine hydrochloride; phosphodiesterases inhibitor; learning enhancement, cognition activator; improving perception, concentration, or memory | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-03 | — | — | US | disclosed |
| US-20110207735-A1 | CYANOPYRIMIDINONES | HENDRIX MARTIN | 2011-08-25 | — | — | US | disclosed |
| US-20110207735-A1 | CYANOPYRIMIDINONES | HENDRIX MARTIN | 2011-08-25 | — | — | US | disclosed |
| US-20080255118-A1 | Cyanopyrimidinones | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255118-A1 | Cyanopyrimidinones | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
| WO-2006125554-A1 | USE OF CYANOPYRIMIDINES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255118-A1 | Cyanopyrimidinones | CACYBP, CHRM4, CHRNA4 | MKNK1 872/4885MKNK2 904/4885JAK2 2860/4885 |
| US-20110207735-A1 | CYANOPYRIMIDINONES | CACYBP, CHRM4, CHRNA4 | MKNK1 872/4885MKNK2 904/4885JAK2 2860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.